ClinicalTrials.gg
CompletedNCT06690996FPABUpdated Jun 23, 2026

A Study of LY4005130 in Healthy Participants

A Phase 1 interventional study of LY4005130 and LY4005130 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it.

Part A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 26 weeks with 14 visits not including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead () ECG. If any values are outside the normal range and considered to be significant, for example, elevated white blood cell count, the respective test may be repeated once at the discretion of the investigator without consultation with the sponsor
  • If enrolled as Japanese or Chinese, the entry requirements are as follows:

    • To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan
    • To qualify as Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
  • Have a body weight 45 kilogram (kg) or greater and greater than 18 and less than 32 kilogram per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Are an individual of (IOCBP)
  • Have known allergies to LY4005130, related compounds, or any components of the formulation
  • Have received a within 28 days of screening or intend to do so during the study or within 28 days after the study

    • Non-live or inactivated vaccinations are allowed
    • Bacillus Calmette Guerin vaccine must not have been administered within 12 months before screening
  • Had a surgical procedure within 12 weeks before screening;

    • during the study, or
    • within 28 days after the study
  • Have a history of allergy to medications that could be used to treat infusion reactions, or to the drug
  • Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, significant history of atopy, or a history of severe posttreatment reactions. These reactions include, but are not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis
  • Have a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions

    • Basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years, or
    • Cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening
  • Have had breast cancer within the past 10 years
  • Have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant
  • Have a current or recent acute, active infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    LY4005130 Part A (SAD) SC

    A single-ascending dose of LY4005130 administered subcutaneously (SC)

    Drug: LY4005130

  • Placebo comparator
    Placebo Part A (SAD) SC

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY4005130 Part A (SAD) IV

    A single-ascending dose of LY4005130 administered intravenously (IV)

    Drug: LY4005130

  • Placebo comparator
    Placebo Part A (SAD) IV

    Placebo administered IV

    Drug: Placebo

  • Experimental
    LY4005130 Part A (SAD) Optional

    A single-ascending dose of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts

    Drug: LY4005130

  • Placebo comparator
    Placebo Part A (SAD) Optional

    A single-ascending dose of placebo administered either SC or IV depending on emerging data from earlier cohorts

    Drug: Placebo

  • Experimental
    LY4005130 Part B (MAD) IV

    Multiple-ascending doses of LY4005130 administered IV

    Drug: LY4005130

  • Placebo comparator
    Placebo Part B (MAD) IV

    Placebo administered IV

    Drug: Placebo

  • Experimental
    LY4005130 Part B (MAD) SC or IV

    Multiple-ascending doses of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts

    Drug: LY4005130

  • Placebo comparator
    Placebo Part B (MAD) SC or IV

    Multiple-ascending doses of placebo administered either SC or IV depending on emerging data from earlier cohorts

    Drug: Placebo

  • Experimental
    LY4005130 Part B (MAD) Optional

    Multiple-ascending doses of LY4005130 administered either SC or IV depending on emerging data from earlier cohorts

    Drug: LY4005130

  • Placebo comparator
    Placebo Part B (MAD) Optional

    Multiple-ascending doses of placebo administered either SC or IV depending on emerging data from earlier cohorts

    Drug: Placebo

Interventions

  • Administered IV

  • Administered SC

  • DrugPlacebo

    Administered IV

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to Study Completion (Up to 26 Weeks)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4005130

    Cmax of LY4005130

    Time frame: Baseline to Study Completion (Up to 26 Weeks)

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY4005130

    AUC of LY4005130

    Time frame: Baseline to Study Completion (Up to 26 Weeks)

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Apr 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 15, 2024
StartActual
Nov 8, 2024
Primary completionActual
Apr 28, 2026
CompletionActual
Apr 28, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06690996
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Nov 8, 2024
Primary completion
Apr 28, 2026
Completion
Apr 28, 2026
Last update
Jun 23, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4005130

Start the discussion